Krystal Biotech
KRYS
299 hedge funds and large institutions have $4.98B invested in Krystal Biotech in 2025 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 88 increasing their positions, 113 reducing their positions, and 27 closing their positions.
207% more call options, than puts
Call options by funds: $54.2M | Put options by funds: $17.6M
133% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 27
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
14% more capital invested
Capital invested by funds: $4.35B → $4.98B (+$626M)
13% more funds holding
Funds holding: 264 → 299 (+35)
0.75% less ownership
Funds ownership: 96.57% → 95.83% (-0.75%)
22% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 113
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$61.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$33.7M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$31.2M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$22.9M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$45.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$27.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$26.6M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$19.1M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$16.8M |
KRYS Hedge Fund Activity: Q1 2025 in Review
299 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2025, worth a combined $4.98B — up 14% from $4.35B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new KRYS positions and 27 closed out — a net gain of 36 holders — while 88 added to existing stakes and 113 trimmed.
The largest buyer was UBS AM, adding an estimated $61.4M. The largest seller was Jennison Associates, cutting an estimated $45.4M.
- 299 institutional investors held Krystal Biotech (KRYS) as of Q1 2025, up from 264 in Q4 2024.
- Funds reported $4.98B of Krystal Biotech stock for Q1 2025, up 14% quarter-over-quarter.
- 63 funds opened new Krystal Biotech positions in Q1 2025 and 27 closed out, a net change of +36 holders.
- The largest Krystal Biotech buyer in Q1 2025 was UBS AM, an estimated $61.4M added.
- The largest Krystal Biotech seller in Q1 2025 was Jennison Associates, an estimated $45.4M sold.
Based on aggregated 13F filings for Q1 2025.